Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of cfDNA as a Marker of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

NCT04319354 is registered in ClinicalTrials.gov with Hospital Pedro Hispano as lead sponsor.

NCT NCT04319354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04319354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of cfDNA as a Marker of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Lead sponsor
Hospital Pedro Hispano
Phase
Not applicable
Overall status
Completed
Start date
November 18, 2019
Completion date
December 30, 2021
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of rectum